To explore the mechanism driving superior tumor control with BATF3 OE, we repeated the in vivo experiment with T cells from two different donors and phenotypically characterized the CAR T cells before treatment and after collecting tumor-infiltrating CAR T cells on day 3 and day 19 post-treatment (Fig. 5d–k, Extended Data Fig. 9 and Supplementary Fig. 9). Here, BATF3 is linked to neoplasm.